Amyloid precursor-like protein 2 suppresses irradiation-induced apoptosis in Ewing sarcoma cells and is elevated in immune-evasive Ewing sarcoma cells

Cancer Biology and Therapy

Volumn 14, Issue 8, 2013, Pages 752-760

  Peters, Haley L ^a,c   Yan, Ying ^a   Nordgren, Tara M ^a,b   Cutucache, Christine E ^a,d   Joshi, Shantaram S ^a   Solheim, Joyce C ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Amyloid precursor like protein 2; Cytotoxic; Ewing sarcoma; Immune evasion; Immunotherapy; Lymphokine activated killer cell; Radiation

Indexed keywords

AMYLOID PRECURSOR LIKE PROTEIN 2; AMYLOID PRECURSOR PROTEIN; CD56 ANTIGEN; INTERLEUKIN 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; CULTURAL ANTHROPOLOGY; CYTOTOXIC T LYMPHOCYTE; DNA CONTENT; EFFECTOR CELL; EWING SARCOMA; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; PROTEIN EXPRESSION;

AMYLOID PRECURSOR-LIKE PROTEIN 2; CYTOTOXIC; EWING SARCOMA; IMMUNE EVASION; IMMUNOTHERAPY; LYMPHOKINE-ACTIVATED KILLER CELL; RADIATION;

AMYLOID BETA-PROTEIN PRECURSOR; APOPTOSIS; CELL LINE, TUMOR; HUMANS; NERVE TISSUE PROTEINS; SARCOMA, EWING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84881440028     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.25183     Document Type: Article

References (52)

1. Applebaum MA, Goldsby R, Neuhaus J, DuBois SG. Clinical features and outcomes in patients with Ewing sarcoma and regional lymph node involvement. Pediatr Blood Cancer 2012; 59:617-20; PMID:22184129; http://dx.doi.org/10.1002/ pbc.24053
2. Stahl M, Ranft A, Paulussen M, Bölling T, Vieth V, Bielack S, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 2011; 57:549-53; PMID:21442722; http://dx.doi.org/10.1002/ pbc.23040
3. Meltzer PS. Is Ewing's sarcoma a stem cell tumor? Cell Stem Cell 2007; 1:13-5; PMID:18371327; http://dx.doi.org/10.1016/j.stem.2007.05.011
4. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007; 11:421-9; PMID:17482132; http://dx.doi.org/10.1016/j. ccr.2007.02.027
5. Riggi N, Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett 2007; 254:1-10; PMID:17250957; http://dx.doi.org/10.1016/j.canlet.2006.12.009
6. Herrero-Martín D, Osuna D, Ordóñez JL, Sevillano V, Martins AS, Mackintosh C, et al. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br J Cancer 2009; 101:80-90; PMID:19491900; http://dx.doi.org/10.1038/ sj.bjc.6605104
7. Soldatenkov VA, Trofimova IN, Rouzaut A, McDermott F, Dritschilo A, Notario V. Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1. Oncogene 2002; 21:2890-5; PMID:11973649; http://dx.doi. org/10.1038/sj.onc.1205393
8. Sharib JM, Cyrus J, Horvai A, Gray Hazard FK, Neuhaus J, Matthay KK, et al. Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. Pediatr Blood Cancer 2012; 59:611-6; PMID:22180320; http://dx.doi.org/10.1002/pbc.24031
9. Hattangadi J, Esty B, Winey B, Duigenan S, Huang M, Yock T. Radiation recall myositis in pediatric Ewing sarcoma. Pediatr Blood Cancer 2012; 59:570-2; PMID:22021129; http://dx.doi.org/10.1002/pbc.23374
10. Ewing J. Diffuse endothelium of bone. Proc NY Path Soc 1921; 21:17-24.
11. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, et al. Ewing's sarcoma family of tumors: current management. Oncologist 2006; 11:503-19; PMID:16720851; http://dx.doi. org/10.1634/theoncologist.11-5-503
12. Paulussen M, Bielack S, Jürgens H, Casali PG; ESMO Guidelines Working Group. Ewing's sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20(Suppl 4):140-2; PMID:19454436; http://dx.doi. org/10.1093/annonc/mdp155
13. Kovar H, Pospisilova S, Jug G, Printz D, Gadner H. Response of Ewing tumor cells to forced and activated p53 expression. Oncogene 2003; 22:3193-204; PMID:12761489; http://dx.doi.org/10.1038/sj.onc.1206391
14. Veeraraghavan J, Natarajan M, Herman TS, Aravindan N. Curcumin-altered p53-response genes regulate radiosensitivity in p53-mutant Ewing's sarcoma cells. Anticancer Res 2010; 30:4007-15; PMID:21036715
15. Soldatenkov V, Notario V, Dritschilo A. Expression of the human Bcl-2 increases resistance of Ewing's sarcoma cells to apoptosis and inhibits poly(ADP-ribose) polymerase cleavage induced by radiation. Int J Oncol 1996; 9:547-51; PMID:21541549
16. Attawia MA, Borden MD, Herbert KM, Katti DS, Asrari F, Uhrich KE, et al. Regional drug delivery with radiation for the treatment of Ewing's sarcoma. In vitro development of a taxol release system. J Control Release 2001; 71:193-202; PMID:11274751; http://dx.doi. org/10.1016/S0168-3659(01)00217-6
17. Atzpodien J, Gulati SC, Shimazaki C, Bührer C, Oz S, Kwon JH, et al. Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing. Oncology 1988; 45:437-43; PMID:3263598; http://dx.doi.org/10.1159/ 000226661
18. Chin T, Toy C, Vandeven C, Cairo MS. Lymphokine-activated killer cytotoxicity in neonatal mononuclear cells: in vitro responses to tumor cell lines from pediatric solid tumors. Pediatr Res 1989; 25:156-60; PMID:2537488; http://dx.doi. org/10.1203/00006450-198902000-00016
19. Kondo S, Miyatake S, Kikuchi H, Oda Y, Iwasaki K, Ohyama K, et al. Mechanism of interferon gammainduced protection of human gliosarcoma cells from lymphokine-activated killer lysis: division of lymphokine-activated killer cells into natural killer-and T-like cells. Neurosurgery 1992; 31:534-40; PMID:1407434; http://dx.doi.org/10.1227/00006123-199209000-00016
20. Joshi AD, Clark EM, Wang P, Munger CM, Hegde GV, Sanderson S, et al. Immunotherapy of human neuroblastoma using umbilical cord blood-derived effector cells. J Neuroimmune Pharmacol 2007; 2:202-12; PMID:18040845; http://dx.doi.org/10.1007/s11481-006-9038-y
21. Foreman NK, Rill DR, Coustan-Smith E, Douglass EC, Brenner MK. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer 1993; 67:933-8; PMID:8494726; http://dx.doi.org/10.1038/bjc.1993.173
22. Belova OB, Vinnichuk UD, Shlakhovenko VA, Berezhnaya NM. Efficacy of different immunotherapy approaches toward treatment of doxorubicin-resistant and doxorubicin-sensitive transplantable rhabdomyosarcoma. Exp Oncol 2007; 29:272-6; PMID:18199982
23. Berdeja JG, Hess A, Lucas DM, O'Donnell P, Ambinder RF, Diehl LF, et al. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res 2007; 13:2392-9; PMID:17438098; http://dx.doi.org/10.1158/1078-0432.CCR-06-1860
24. Bertelli R, Neri F, Tsivian M, Ruhrman N, Cavallari G, Beltempo P, et al. Endolymphatic immunotherapy in inoperable hepatocellular carcinoma. Transplant Proc 2008; 40:1913-5; PMID:18675087; http://dx.doi. org/10.1016/j.transproceed. 2008.05.049
25. Hirooka Y, Itoh A, Kawashima H, Hara K, Nonogaki K, Kasugai T, et al. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas 2009; 38:e69-74; PMID:19276867; http://dx.doi. org/10.1097/MPA.0b013e318197a9e3
26. Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, Sharp SL, et al. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother 2009; 32:914-9; PMID:19816190; http://dx.doi.org/10. 1097/CJI.0b013e3181b2910f
27. Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, et al. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediatedcytotoxicity (ADCC). Eur J Cancer 2010; 46:1703-11; PMID:20399639; http://dx.doi.org/10.1016/j. ejca.2010.03.005
28. Yin X, Ouyang S, Xu W, Zhang X, Fok KL, Wong HY, et al. YWK-II protein as a novel G(o)-coupled receptor for Müllerian inhibiting substance in cell survival. J Cell Sci 2007; 120:1521-8; PMID:17452623; http://dx.doi.org/10.1242/ jcs.001230
29. Peters HL, Tuli A, Wang X, Liu C, Pan Z, Ouellette MM, et al. Relevance of amyloid precursor-like protein 2 C-terminal fragments in pancreatic cancer cells. Int J Oncol 2012; 41:1464-74; PMID:22797723
30. Tuli A, Sharma M, McIlhaney MM, Talmadge JE, Naslavsky N, Caplan S, et al. Amyloid precursor-like protein 2 increases the endocytosis, instability, and turnover of the H2-K(d) MHC class I molecule. J Immunol 2008; 181:1978-87; PMID:18641335
31. Tuli A, Sharma M, Capek HL, Naslavsky N, Caplan S, Solheim JC. Mechanism for amyloid precursor-like protein 2 enhancement of major histocompatibility complex class I molecule degradation. J Biol Chem 2009; 284:34296-307; PMID:19808674; http://dx.doi.org/10.1074/jbc.M109.039727
32. Tuli A, Sharma M, Wang X, Simone LC, Capek HL, Cate S, et al. Amyloid precursor-like protein 2 association with HLA class I molecules. Cancer Immunol Immunother 2009; 58:1419-31; PMID:19184004; http://dx.doi.org/10.1007/s00262- 009-0657-z
33. Peters HL, Tuli A, Sharma M, Naslavsky N, Caplan S, MacDonald RG, et al. Regulation of major histocompatibility complex class I molecule expression on cancer cells by amyloid precursor-like protein 2. Immunol Res 2011; 51:39-44; PMID:21826533; http://dx.doi. org/10.1007/s12026-011-8238-6
34. Wu W, Song W, Li S, Ouyang S, Fok KL, Diao R, et al. Regulation of apoptosis by Bat3-enhanced YWK-II/APLP2 protein stability. J Cell Sci 2012; 125:4219-29; PMID:22641691; http://dx.doi.org/10.1242/jcs.086553
35. Covell DG, Wallqvist A, Rabow AA, Thanki N. Molecular classification of cancer: unsupervised selforganizing map analysis of gene expression microarray data. Mol Cancer Ther 2003; 2:317-32; PMID:12657727
36. Mauri P, Scarpa A, Nascimbeni AC, Benazzi L, Parmagnani E, Mafficini A, et al. Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB J 2005; 19:1125-7; PMID:15985535
37. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45:321-34; PMID:163658
38. McLoughlin DM, Miller CC. The FE65 proteins and Alzheimer's disease. J Neurosci Res 2008; 86:744-54; PMID:17828772; http://dx.doi.org/10.1002/jnr.21532
39. Orcholski ME, Zhang Q, Bredesen DE. Signaling via amyloid precursor-like proteins APLP1 and APLP2. J Alzheimers Dis 2011; 23:689-99; PMID:21178287
40. Chong AS, Scuderi P, Grimes WJ, Hersh EM. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor. J Immunol 1989; 142:2133-9; PMID:2493506
41. Mingari MC, Ferrini S, Pende D, Bottino C, Prigione I, Moretta A, et al. Phenotypic and functional analysis of human CD3+ and CD3-clones with "lymphokineactivated killer" (LAK) activity. Frequent occurrence of CD3+ LAK clones which produce interleukin-2. Int J Cancer 1987; 40:495-8; PMID:3117711; http://dx.doi.org/10.1002/ijc.2910400411
42. Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H, et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 2008; 45:3917-25; PMID:18657862; http://dx.doi.org/10.1016/j.molimm.2008.06.016
43. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010; 16:3901-9; PMID:20542985; http://dx.doi. org/10.1158/1078-0432.CCR-10-0735
44. Handa K, Suzuki R, Matsui H, Shimizu Y, Kumagai K. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production. J Immunol 1983; 130:988-92; PMID:6294182
45. Stante M, Minopoli G, Passaro F, Raia M, Vecchio LD, Russo T. Fe65 is required for Tip60-directed histone H4 acetylation at DNA strand breaks. Proc Natl Acad Sci U S A 2009; 106:5093-8; PMID:19282473; http://dx.doi.org/10.1073/ pnas.0810869106
46. Hallett WH, Murphy WJ. Natural killer cells: biology and clinical use in cancer therapy. Cell Mol Immunol 2004; 1:12-21; PMID:16212916
47. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9:495-502; PMID:18425106; http://dx.doi.org/10. 1038/ni1581
48. Shresta S, MacIvor DM, Heusel JW, Russell JH, Ley TJ. Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. Proc Natl Acad Sci U S A 1995; 92:5679-83; PMID:7777569; http://dx.doi. org/10.1073/pnas.92.12.5679
49. Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ. How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 1998; 10:581-7; PMID:9794837; http://dx.doi.org/10.1016/S0952-7915(98)80227-6
50. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20:323-70; PMID:11861606; http://dx.doi.org/10.1146/annurev. immunol.20.100201.131730
51. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A 2001; 98:635-40; PMID:11149963; http://dx.doi. org/10.1073/pnas.98.2.635
52. Yan Y, Spieker RS, Kim M, Stoeger SM, Cowan KH. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation. Oncogene 2005; 24:3285-96; PMID:15735702; http://dx.doi.org/10.1038/sj.onc.1208492